"Precise medical" standing on the ventricle

On the evening of August 6, Qianshan Pharmaceutical Co., Ltd. released the 2015 interim report. As the transformation of precision medical treatment achieved initial results, during the reporting period, operating income increased by 21.73% year-on-year, net profit increased by 154.4% year-on-year, and the “precision medical ” sector is expected to be all year round. Revenue will exceed 25% of the company's total revenue.

In fact, since the beginning of this year, "precise medical care" has been chased by various capitals. According to incomplete statistics, there are currently 26 listed companies involved in “precise medical care”. The agency research report predicts that the global precision medical market will be nearly 60 billion US dollars in 2015, and the growth rate is expected to be 15% in the next five years, which is three to four times the overall growth rate of the pharmaceutical industry. The growth rate of the genetic sequencing industry will exceed 20%.

However, some insiders pointed out that although the prospects for precision medicine are very good, the process of implementation is extremely complicated, and the level of development is also uneven. For example, Jilin Jidong began investing artificial liver many years ago, but the bioartificial liver project still needs Approved by the State Food and Drug Administration. Academician Zhan Qimin, deputy dean of the Chinese Academy of Medical Sciences and director of the State Key Laboratory of Molecular Oncology, pointed out that data sharing and sharing of biological samples are the bottlenecks in the development of precision medicine.

100 billion market opened

One of the hottest words in the medical industry this year is the "precise medical" and "gene sequencing" mentioned by Obama at the beginning of the year.

The industry believes that precision medicine is an emerging means of disease prevention and treatment based on information about individual genes, environment and lifestyle. Genetic testing is a conventional weapon for achieving precision medicine. Through genetic testing, it is possible to accurately attack the right medicine.

“The innovation of human genomics technology and the emergence of big data analysis tools have provided conditions for precision medicine.” A fund manager from a medical researcher in Shanghai told 21st Century Business Herald that precision medicine is a concern in many segments. One aspect of it.

The industry also believes that "precise medical care" has a huge potential market.

Southwest Securities Research Report pointed out that in 2015, the global precision medical market will be nearly 60 billion US dollars, and the growth rate in the next five years is expected to be 15%, which is three to four times the overall growth rate of the pharmaceutical industry. The growth rate of the gene sequencing industry will exceed 20%. If the domestic diagnosis of genetics and tumor treatment are liberalized, its market capacity is beyond imagination. Among them, the market for newborn screening alone exceeds 30 billion, and the relevant domestic industries are just getting started. The global market for tumor immunotherapy is as high as $30 billion.

In fact, Obama’s remarks about “precise medical care” are based on his medical expenses and so on. In his January 30 speech, Obama cited a data from a study: the return per dollar spent on the Human Genome Project was $140. "This innovation has received huge economic returns, and there is absolutely nothing wrong with applauding this innovation."

For "precise medical care", China also has its own understanding .

According to Dong Jiahong, executive director of Beijing Tsinghua Chang Gung Memorial Hospital, precision medical treatment is a scientific method that selects appropriate medical treatment, minimizes damage to medical resources, minimizes medical expenses, and maximizes patient recovery.

In fact, China is also actively promoting technological breakthroughs in precision medicine and gene sequencing.

For example, on July 31, the Health and Medical Management Division of the Health and Family Planning Commission issued the "Technical Guidelines for Gene Detection of Drug Metabolizing Enzymes and Drug Targets (Trial)" and "Technical Guidelines for Individualized Treatment of Tumors (Trial)". The purpose is to Further improve the standardization level of drug metabolism enzymes and drug target gene detection technologies in clinical laboratories and gene detection technology for individualized cancer drugs.

Previously, there were also a series of promotion policies. For example, on March 27, 2015, China released the list of the first batch of clinical pilot units for high-throughput gene sequencing technology for tumor diagnosis and treatment projects; on April 15, 2015, the Health Planning Commission and the Ministry of Science and Technology Organize experts in the fields of biomedicine and other departments to discuss precision medical research plans with the Chinese Academy of Sciences and other departments.